Ruxience label. Rituximab (Ruxience) monotherapy is indicated for treatment of patients with s...
Ruxience label. Rituximab (Ruxience) monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Ruxience, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA. It is given by IV infusion by a healthcare provider. ","761103","BLA","RUXIENCE","RITUXIMAB-PVVR","3","SUPPL ","http://www. Also find the prescribing information, announcements, resources, and channels to connect with Pfizer Medical. Jun 18, 2025 ยท RUXIENCE, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL. Coverage will be provided for Riabni, Ruxience, or Truxima contingent on the coverage criteria in the Diagnosis-Specific Criteria section. icated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. Find information about RUXIENCE® (rituximab-pvvr) infusion, an FDA-approved biosimilar of RITUXAN® (rituximab), on the HCP site. nagchipvnqnlymjagpcpeokbzoeferrgawnrttllpvofklbiwazdiezfg